Stock & Company Details
Apimeds Pharmaceuticals US $APUS
Price:
N/A
N/A
1.5M
$4.6M
52 Week High:
N/A
10 Day Average Volume:
N/A
-0.51
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
N/A
APUS technical indicators
Latest Apimeds Pharmaceuticals US (APUS) indicator readings as of 2026-10-29.
APUS's 14-day RSI is 44.5, in neutral territory. At $3.21 it is trading 36.6% above its 200-day moving average of $2.35, and below its 50-day average of $3.73. Price sits in the middle of its Bollinger Bands ($1.67 to $6.71). ADX reads 18.5, indicating a range-bound market rather than a trend.
Overview
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Finance Bot
Ask your questions
Start by typing a question below.
